Recent Updates
Recently added Catalysts

SEA-CD70

Phase 1

Myelodysplastic Syndrome | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Jul 22, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
CONTROLLED
Total Trials1
Total Enrollment178
FDA Designations
No designations recorded
Clinical trial landscape

SEA-CD70 · 1 trial · 2 indications

Phase 1 1
NCT04227847A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesMyelodysplastic Syndrome
RECRUITING178 Analytics
PHASE1RECRUITING
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Myelodysplastic Syndrome
NCT04227847178
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of participants with adverse events (AEs)
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Number of participants with laboratory abnormalities
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years

To be summarized using descriptive statistics.

Number of participants with a dose-limiting toxicity (DLT) at each dose level (Parts A and D only)
Though end of DLT evaluation period; up to approximately 4 weeks

To be summarized using descriptive statistics.

Secondary Endpoints
AUC - Area under the plasma concentration-time curve
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Tmax - Time to maximum concentration attained
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Cmax - Maximum observed plasma concentration
Through 30-37 days following last dose of SEA-CD70; up to approximately 2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part AEXPERIMENTALSEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
Part BEXPERIMENTALSEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
Part CEXPERIMENTALSEA-CD70 expansion cohort in relapsed/refractory AML
Part DEXPERIMENTALSEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or MDS/AML, and previously untreated higher-risk MDS or MDS/AML
Part EEXPERIMENTALSEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS or MDS/AML
Part FEXPERIMENTALSEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or MDS/AML
Part GEXPERIMENTALSEA-CD70 + azacitidine +venetoclax dose-finding/dose optimization in previously untreated and unfit for induction therapy AML
Interventions
NameTypeDescription
SEA-CD70DRUGGiven into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
azacitidineDRUG75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
VenetoclaxDRUG400 mg /day PO, continuously; administered with ramping
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites53

Part A Inclusion Criteria * Participants with cytologically/histologically confirmed MDS (2016 World Health Organization (WHO) classification) with * Measurable disease per WHO MDS with excess blasts criteria * MDS that is relapsed or refractory and must not have other therapeutic options * ...

Countries:United StatesJapanNetherlands
Unlock Eligibility Criteria
Competitive Landscape -Myelodysplastic Syndromes 76 trials (matched to "Myelodysplastic Syndrome")

Top 20 of 33 competitors

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY10PHASE3Luspatercept
AbbVie, Inc.ABBV3PHASE3Venetoclax, Azacitidine
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK4PHASE3Elritercept, Epoetin Alfa
argenx SE Sponsored ADRARGX1PHASE3Empasiprubart, IVIG
Incyte CorporationINCY4PHASE2Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E
Novartis AG Sponsored ADRNVS2PHASE2decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax
Geron CorporationGERN3PHASE2Imetelstat
GSK plc Sponsored ADRGSK1PHASE2Momelotinib
Agios Pharmaceuticals, Inc.AGIO1PHASE2Tebapivat
ICON PlcICLR1PHASE2SP-420
Ascentage Pharma Group International Unsponsored ADRAAPG2PHASE3Lisaftoclax, Azacitidine
Tango Therapeutics, Inc.TNGX2PHASE3Ivosidenib, Azacitidine
Johnson & JohnsonJNJ3PHASE1JNJ-89853413
Eli Lilly and CompanyLLY1PHASE1LY3410738, Venetoclax, Azacitidine
Disc Medicine, Inc.IRON1PHASE1DISC-0974
TScan Therapeutics, Inc.TCRX2PHASE1Undisclosed
Pfizer Inc.PFE1PHASE1SEA-CD70, azacitidine, Venetoclax
Precigen IncPGEN1PHASE1PRGN-3006 T Cells
AstraZeneca PLCAZN1PHASE1AZD3632, Posaconazole
Foghorn Therapeutics, Inc.FHTX1PHASE1FHD-286, Low Dose Cytarabine, Decitabine
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJul 22, 2026NCT04227847lastUpdatePostDate: changed
LOWJul 22, 2026NCT04227847lastUpdatePostDate: changed
LOWMay 26, 2026NCT04227847primaryCompletionDate: changed
LOWMay 24, 2026NCT04227847studyFirstPostDate: changed